Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial [CNBC]
DexCom, Inc. (DXCM)
Last dexcom, inc. earnings: 4/28 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
dexcom.com/investors
Company Research
Source: CNBC
Subscribe here to receive future editions. Analysts say Eli Lilly may have a future blockbuster drug on its hands: An experimental pill designed to lower an inherited form of high cholesterol. The pharmaceutical giant presented mid-stage trial data on the pill , muvalaplin, at the American Heart Association Scientific Sessions meeting in Chicago on Monday. The treatment demonstrates the diversity of Eli Lilly's drug pipeline beyond its top-selling weight loss and diabetes treatments. Here's what makes the daily pill so important: Muvalaplin is the only oral treatment among several injectable therapies being developed to treat high levels of lipoprotein(a) – or Lp(a) – in the blood, an inherited risk factor for heart disease. That includes Eli Lilly's own late-stage injectable drug, lepodisiran , and injections from Novartis and Amgen About one in five Americans , or 63 million people, have elevated levels of Lp(a), according to the Family Heart Foundation. There are currentl
Show less
Read more
Impact Snapshot
Event Time:
DXCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXCM alerts
High impacting DexCom, Inc. news events
Weekly update
A roundup of the hottest topics
DXCM
News
- Medtronic (MDT) Q2 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Oura Ring Major Update To Integrate Key Feature: Blood Sugar Monitoring [Forbes]Forbes
- Dexcom invests $75m in OURA to forge partnership [Yahoo! Finance]Yahoo! Finance
- Oura CEO on new partnership with Dexcom [CNBC]CNBC
- Dexcom and OURA Announce Strategic Partnership [Yahoo! Finance]Yahoo! Finance
DXCM
Earnings
- 10/24/24 - Miss
DXCM
Sec Filings
- 11/18/24 - Form 4
- 11/15/24 - Form 144
- 10/24/24 - Form 10-Q
- DXCM's page on the SEC website